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The Autism Genetic Resource Exchange: A Resource
for the Study of Autism and Related Neuropsychiatric
Conditions
To the Editor:
In this letter, we describe the Autism Genetic Resource
Exchange (AGRE), a resource for the study of autism
and pervasive developmental disorder (PDD). Autism
presents within the first 3 years of life, is characterized
by qualitative impairments in communication and social
interaction—in the presence of restricted repetitive and
stereotyped patterns of behavior, interests, and activi-
ties—and is part of a spectrum of disorders that includes
Asperger syndrome and PDD (American Psychiatric As-
sociation 1994). Estimates of the prevalence of autism
in the general population ranges from 0.04% to 10.l%
(Bryson et al. 1988; Gillberg et al. 1991). Twin and
family studies have demonstrated that the genetic con-
tribution to autism and PDD is significant, with an MZ-
twin concordance of 60%–90% and a 45- to 150-fold
increase in risk to siblings (Ritvo et al. 1989; Jorde et
al. 1990; Bailey et al. 1995). Thus, molecular genetic
studies of autism-spectrum disorders are likely to con-
tribute significantly to our understanding of this con-
dition, as the recent results of several independent ge-
nome scans suggest (International Molecular Genetic
Study of Autism Consortium 1998; Barrett et al. 1999;
Philippe et al. 1999; Risch et al. 1999).
AGRE has been developed as a joint effort of the Cure
Autism Now (CAN) Foundation and the Human Bio-
logical Data Interchange (HBDI), to facilitate collabo-
rative genetic research into the etiology of autism and
PDD and to make biomaterials from well-characterized
families with autism widely available to the scientific
community, so as to accelerate research. Since genetic
studies of complex neuropsychiatric conditions are lim-
ited by the large sample sizes needed to attain adequate
power (Lander and Kruglyak 1995; Risch and Meri-
kangas 1996), the consolidation of large numbers of
families into one collection that is made available to
researchers at a fraction of the cost originally incurred
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Figure 1 Sample AGRE pedigree. A typical AGRE pedigree is
depicted, with the identifying numbers given directly underneath the
individuals. The second number refers to the following key, as defined
by ADI scores: 1 p verbal; 2p nonverbal; 3p regression; and 4p
late onset. The HI numbers are actual coded database numbers that
uniquely identify each individual. The availability of biomaterials is
also indicated if the family was corecruited with another academic
group—in this case, Mt. Sinai (AGRE Web site).
Table 1
Patient Recruitment and Availability










a Consented and scheduled for ADI and blood
draw.
b ADI complete, biomaterials complete, quality
controlled and available for distribution.
c Incomplete biomaterials or ADI.
in their ascertainment and collection is of great value to
the community.
One unique feature of AGRE, which has enabled the
rapid ascertainment of large numbers of families, has
been the development of a protocol and the infrastruc-
ture to conduct the majority of the evaluations and blood
draws in the families’ homes. This process may prove
useful for more-rapid family ascertainment in studies of
other neuropsychiatric conditions (AGRE Web site). To
date, ∼400 multiplex families with autism and PDD are
in various stages of clinical evaluation, with DNA col-
lection completed (table 1). Both an online and a hard-
copy catalogue are available, containing the pedigrees
in the collection, with notations of affectation status and
basic phenotypic features, such as language delay. A
sample pedigree is depicted in figure 1. Biomaterials from
343 of these completed families are currently available
to the scientific research community, and this resource
continues to expand, with the goal of 500 families by
the end of the year 2001. Family biomaterials for the
AGRE program are housed at the HBDI Repository at
Rutgers University, under the direction of Jay Tischfield.
Quality-controlled samples, including immortalized cell
lines (1 # 106 cells/ampoule), 20-mg aliquots of DNA,
and 50-ml aliquots of sera, are available to the research
community by simple application, which requires proof
of institutional review board (IRB) approval. Samples
are available to academia and industry, and significant
discounts, as well as limited grants to support academic
use of the resource, are available to academic researchers
through the CAN Foundation. To facilitate collabora-
tion, free samples are available to researchers who de-
posit their collections in AGRE through the Sharing Re-
searcher Program.
Scientific oversight for the program is provided by a
Steering Committee, which includes researchers from the
fields of genetics and autism. Human subjects protection
oversight is provided by the IRB at the University of Penn-
sylvania School of Medicine. In addition to providing
researchers with biomaterials, a major effort has been
undertaken to develop a state-of-the-art, Internet-acces-
sible database of detailed clinical information. Phenotypic
assessment is ongoing and includes the two examinations
that are completed by all of the NIH autism collaborative
groups: the Autism Diagnostic Interview–Revised (ADI-
R) (Lord et al. 1994) and the Autism Diagnostic Obser-
vational Schedule (ADOS) (Lord et al. 2000). All ADI
and ADOS raters undergo ongoing reliability checks to
prevent any drift in diagnosis (Lord et al. 1994, 2000).
In addition, photographic dysmorphology, physical and
neurological examination, and medical and family history
are being collected by pediatric neurologists. Probands
with possible secondary autism resulting from perinatal
trauma, from an identified genetic syndrome, or from
other medical causes are noted, although this is only a
small percentage of cases. Currently, the ADI data and a
subset of the ADOS data, both coded for confidentiality,
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are available online for researcher access through the
AGRE Web site. Online phenotypic databases for the re-
mainder of the data collected are being developed and
will be available in 6 mo. More information on the
timeline of data and material collection is available at the
Web site. We are striving to improve the utility of AGRE,
and user feedback is an important element in this process.
Fragile-X testing is conducted in all families (Brown
et al. 1986), and cytogenetic analysis—including FISH
for 15q and telomere screening—is commencing. Of 220
families tested, 3 have subjects that carry a fragile-X
expansion (1.3%; W. T. Brown, unpublished data). A
genome scan at an average 10-cM resolution has been
completed on the first 132 families in the collection (T.
C. Gilliam, personal communication), and genotype data
from 188 families are available online at the AGRE Web
site. As genome scans on additional families are com-
pleted, these data will be updated regularly, and inves-
tigators accessing these data will be notified of the up-
dates automatically. More information regarding this
resource, including pricing of samples and access to the
resource, can be obtained from the CAN Foundation
and AGRE Web sites, or by contacting the authors.
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